

5-DIAZO-6,6-DIMETHYL-4-OXO- 4,5,6,7-TETRAHYDROINDAZOLES IN [3+2] CYCLOADDITION REACTIONS

I. Strakova¹, A. Strakovs¹, M. Petrova², and S. Belyakov²

The [3+2] cycloaddition reactions of a series of 1,3-substituted 5-diazo-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindazoles with maleic anhydride and dimethyl acetylenedicarboxylate gave 1',3'-substituted 3-spiro[4,6-dioxo-4,6,3a,6a-tetrahydro-3H-furo[3,4-c]pyrazole]-5'-[6',6'-dimethyl-4'-oxo-4',5',6',7'-tetrahydroindazoles] and 1',3'-substituted 3-spiro[4,5-di(methoxycarbonyl)-3H-pyrazole]-5'-[6',6'-dimethyl-4'-oxo-4',5',6',7'-tetrahydroindazoles] respectively. When heated the former eliminate nitrogen and are transformed into 1',3'-substituted 6-spiro[2,4-dioxo-3-oxabicyclo[3.1.0]hexane]-5'-[6',6'-dimethyl-4'-oxo-4',5',6',7'-tetrahydroindazoles].

Keywords: dimethyl acetylenedicarboxylate, 1,3- and 2,3-substituted 5-diazo-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindazoles, maleic anhydride, [3+2] cycloaddition.


In the last ten years the range of indazole derivatives with valuable biological activity has increased substantially. Among them agonists of estrogen receptors [1] and dopamine D3 receptors [2], HIV protease inhibitors [3], and new anti-inflammatory substances [4] have been discovered. In this connection in a continuation of researches on the synthesis of 4,5-bifunctional 6,7-dihydro- and 4,5,6,7-tetrahydroindazoles [5-10] we realized [3+2] cycloaddition reactions between 5-diazo-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindazoles **1a-d** and maleic anhydride.

The diazoindazoles **1a,b,d** were obtained by the decomposition of the corresponding tosylhydrazones **2a,b,d** in a water-ethanol solution of sodium hydroxide according to the procedure in [11, 12] that we used earlier for the preparation of the diazoindazoles **1c** and **3**.

In the reaction of the diazoindazoles **1a-d** with maleic anhydride by the classical methods [13, 14] the corresponding 1',3'-substituted 6',6'-dimethyl-4,6,4'-trioxo-4,6,3a,6a,4',5',6',7'-octahydro-3H-spirofuro[3,4-c]-pyrazole-3,5'-indazoles **4a-d** are formed. The reactions were carried out by keeping equimolar amounts of the reagents in methylene chloride for 15 days. The precipitated spiro compound **4** was filtered off and recrystallized from ethyl acetate with minimal boiling.

Heating of the pyrazolines **4b,c** for 1-2 min at the melting point or boiling in toluene led to the release of nitrogen and transformation into the corresponding 1',3'-substituted 6',6'-dimethyl-2,4,4'-trioxo-4',5',6',7'-tetrahydrospiro-3-oxabicyclo[3.1.0]hexane-6,5'-indazoles **5b,c**.

¹Riga Technical University, Riga LV-1048, Latvia; e-mail: strakovs@latnet.lv. ²Latvian Institute of Organic Synthesis, Riga LV-1006; e-mail: marina@osi.lv. Translated from *Khimiya Geterotsiklicheskih Soedinenii*, No. 12, pp. 1784-1791, December, 2007. Original article submitted March 17, 2006.



1, 2, 4 a R = Ph, R¹ = H; **b** R = Ph, R¹ = Me; **c** R = Py-2, R¹ = Me; **d** R = C₆H₃(CF₃)₂-3,5, R¹ = Me; **3, 7 a** R = 2- pyridyl, R¹ = Ph; **b** R = Ph, R¹ = C₆H₄OMe-4; **5 b** R = Ph, R¹ = Me; **c** R = Py-2, R¹ = Me; **6 c** R = Py-2, R¹ = Me; **d** R = C₆H₃(CF₃)₂-3,5, R¹ = Me; **8** R = Ph, R¹ = Me, R² = R³ = COOH; **9** R = 2- pyridyl, R¹ = Me, R² = COOH, R³ = CONHCH₂Ph

Heating of the solution of the anhydride **5b** in 5% aqueous sodium hydroxide solution to boiling followed by acidification leads to the dicarboxylic acid **8**. The benzylamide **9** is formed when a benzene solution of equimolar amounts of the anhydride **5c** and benzylamine is heated to boiling.

The reaction of the diazoindazoles **1b,c** and **3a,b** [12] with dimethyl acetylenedicarboxylate is carried out by keeping equimolar amounts of the reagents in methylene chloride at 20°C for 4-5 days. In all cases the corresponding 1',3'- or 2',3'-substituted 4,5-di(methoxycarbonyl)-6,6'-dimethyl-4'-oxo-4',5',6',7'-tetrahydro-3H-spiropyrazole-3,5'-indazoles **6c,d** and **7a,b** were obtained.

TABLE 1. The Characteristics of the Synthesized Compounds

Com- pound	Empirical formula	Found, %			mp, °C	Yield, %
		Calculated, %				
		C	H	N		
1a	C ₁₅ H ₁₄ N ₄ O	67.51	5.35	20.88	174-175	73
		67.65	5.30	21.04		
1b	C ₁₆ H ₁₆ N ₄ O	68.37	5.55	20.08	145-147	63
		68.55	5.75	19.99		
1d	C ₁₈ H ₁₄ F ₆ N ₄ O	51.70	3.30	13.25	185-187	69
		51.93	3.39	13.46		
2a	C ₂₂ H ₂₂ N ₄ O ₃ S	62.63	5.11	13.12	118-119	88
		62.55	5.25	13.26		
2b	C ₂₃ H ₂₄ N ₄ O ₃ S	63.11	5.40	12.75	149-151	70
		63.28	5.54	12.84		
2d	C ₂₅ H ₂₂ F ₆ N ₄ O ₃ S	52.27	3.90	9.66	160-162	41
		52.44	3.87	9.79		
4a	C ₁₉ H ₁₆ N ₄ O ₄	62.45	4.30	15.31	167-169 (dec.)	51
		62.63	4.43	15.38		
4b	C ₂₀ H ₁₈ N ₄ O ₄	63.26	4.59	14.70	179–181 (dec.)	50
		63.48	4.79	14.81		
4c	C ₁₉ H ₁₇ N ₅ O ₄	60.01	4.58	18.35	154-156 (dec.)	68
		60.15	4.52	18.46		
4d	C ₂₂ H ₁₆ F ₆ N ₄ O ₄	51.19	3.03	10.93	162-164 (dec.)	40
		51.37	3.14	10.89		
5b	C ₂₀ H ₁₈ N ₂ O ₄	68.44	5.02	7.85	202-204	43
		68.56	5.18	7.99		
5c	C ₁₉ H ₁₇ N ₃ O ₄	64.70	4.68	11.80	257-258	56
		64.95	4.88	11.96		
6c	C ₂₁ H ₂₁ N ₅ O ₅	59.39	4.92	16.36	159-160	95
		59.56	5.00	16.54		
6d	C ₂₄ H ₂₀ F ₆ N ₄ O ₅	51.49	3.50	9.88	230-231	56
		51.62	3.61	10.03		
7a	C ₂₆ H ₂₃ N ₅ O ₅	64.11	4.60	14.21	185-186	50
		64.32	4.77	14.43		
7b	C ₂₈ H ₂₆ N ₄ O ₆	65.27	5.11	11.03	195-197	45
		65.36	5.09	10.89		
8	C ₂₀ H ₂₀ N ₂ O ₅	65.00	5.33	7.49	252-253	94
		65.21	5.47	7.60		
9	C ₂₆ H ₂₆ N ₄ O ₄	67.93	5.55	12.30	285-287	64
		68.10	5.72	12.22		

The structure of the synthesized compounds was confirmed by the data from the IR and ¹H NMR spectra (Table 2) and in the case of the spiro compound **4c** also by X-ray crystallographic experiments (Table 1).

In the indazole derivatives **4** the methyl groups at C₍₆₎ and also each of the hydrogens of the C₍₇₎ methylene group appear as separate signals. In compounds **5** there are six-proton singlets for the two C₍₆₎ methyl groups and also singlets for the C₍₇₎ methylene groups. The signals of the methyl groups in compounds **5** were assigned according to their ¹³C satellite signals in the ¹H NMR spectra, which make it possible to record ³J_{HH} between the magnetically equivalent protons (4-5 Hz).

The signals for the protons of the furopyrazole structural fragments at the C_(3a) and C_(6a) atoms of compounds **4** are found at δ 3.21-3.76 (3a) and 6.29-6.78 ppm (6a) and for the symmetrical spiro-substituting groups of compounds **5** at δ 3.62-3.67 ppm.

For an objective assessment of the structure of compound **4c** an X-ray crystallographic analysis of the crystals of this compound was undertaken (Fig. 1, Tables 3-5).

TABLE 2. The Spectra of the Synthesized Compounds

Compound	IR spectrum, ν , cm^{-1} (C=O, NH, OH)	^1H NMR spectrum, δ , ppm. (SSCS, J , Hz)*
1a	1630, 2095	1.35 (6H, s, 2CH ₃); 2.96 (2H, s, CH ₂); 7.22-7.70 (5H, m, C ₆ H ₅); 8.06 (1H, s, H-3)
1b	1630, 2090	1.26 (6H, s, 2CH ₃); 2.56 (3H, s, CH ₃); 3.40 (2H, s, CH ₂); 7.50-7.80 (5H, m, C ₆ H ₅)
1c	1640, 2095	1.44 (6H, s, 2CH ₃); 2.53 (3H, s, CH ₃); 3.06 (2H, s, CH ₂); 7.42 (3H, br. s, C ₆ H ₅)
2a	1642, 3230	1.21 (6H, s, 2CH ₃); 2.55 (3H, s, CH ₃); 3.35 (2H, s, CH ₂); 7.28-8.00 (10H, m, C ₆ H ₅ , C ₆ H ₄ , H-3); 12.50 (1H, br. s, NH)
2b	1650, 3260	1.30 (6H, s, 2CH ₃); 2.42 (3H, s, CH ₃); 2.60 (3H, s, CH ₃); 3.45 (2H, s, CH ₂); 7.25-7.80 (9H, m, C ₆ H ₅ , C ₆ H ₄); 12.65 (1H, br. s, NH)
2d	1645, 3250	1.40 (6H, s, 2CH ₃); 2.45 (3H, s, CH ₃); 2.60 (3H, s, CH ₃); 3.50 (2H, s, CH ₂); 7.30-7.95 (7H, m, C ₆ H ₄ , C ₆ H ₅); 12.65 (1H, br. s, NH)
4a	1864, 1782, 1684	0.98 (3H, s, CH ₃); 1.04 (3H, s, CH ₃); 3.18 and 3.28 (2H, two d, $^2J = 12.4$, H-7); (1H, d, $J = 12.4$, H-7); 3.74 (1H, d, $J = 9.6$, H-3a); 6.77 (1H, d, $J = 9.6$, H-6a); 7.53-7.78 (5H, m, Ar); 8.27 (1H, s, H-3a)
4b	1860, 1775, 1670	0.96 (3H, s, CH ₃); 1.27 (3H, s, CH ₃); 2.51 (3H, s, CH ₃); 2.95 (1H, d, $^2J = 16.8$, H-7); 3.28 (1H, d, $J = 10.0$, H-3a); 3.76 (1H, d, $^2J = 16.8$, H-3a); 6.29 (1H, d, $J = 10.0$, H-6a); 7.54 (5H, m, Ar)
4c	1867, 1779, 1671	1.03 (3H, s, CH ₃); 1.09 (3H, s, CH ₃); 2.39 (3H, s, CH ₃); 3.21 (3H, m, CH ₂ , CH); 6.75 (1H, d, $J = 10.0$, H-6a); 7.48 (1H, m, Py); 7.95-8.13 (2H, m, Py); 8.58 (1H, m, $J = 5.0$, Py)
4d	1862, 1775, 1670	0.98 (3H, s, CH ₃); 1.04 (3H, s, CH ₃); 2.41 (3H, s, CH ₃); 3.28 (2H, br. s, CH ₂); 3.74 (1H, d, $J = 10.0$, H-3a); 6.78 (1H, d, $J = 10.0$, H-6a); 8.29 (1H, br. s, Ar); 8.42 (1H, br. s, Ar)
5b	1850, 1772, 1658	0.98 (6H, s, 2CH ₃); 2.37 (3H, s, CH ₃); 3.11 (2H, br. s, H-7); 3.62 (2H, s, H-3a, H-6a); 7.48-7.62 (5H, m, Ar)
5c	1845, 1776, 1658	1.03 (6H, s, 2CH ₃); 2.38 (3H, s, CH ₃); 3.47 (2H, s, H-7); 3.67 (2H, s, H-3a, H-6a); 7.45 (1H, dd, $J = 5.0$, $J = 8.0$, Ar); 7.92 (1H, d, $J = 8.0$, Ar); 8.05 (1H, dt, $J = 8.0$, $J = 2.0$, Ar); 8.56 (1H, d, $J = 5.0$, Ar)
6c	1740, 1720, 1660	1.48 (6H, s, 2CH ₃); 2.66 (3H, s, CH ₃); 3.65 (2H, s, CH ₂); 3.92 (3H, s, OCH ₃); 3.94 (3H, s, OCH ₃); 7.33 (1H, m, Ar); 7.89-7.92 (2H, m, Ar); 8.47 (1H, m, Ar)
6d	1745, 1730, 1662	1.44 (6H, s, 2CH ₃); 2.65 (3H, s, CH ₃); 3.10 (2H, s, CH ₂); 3.92 (6H, s, 2OCH ₃); 7.91 (2H, br. s, Ar); 7.99 (1H, s, Ar)
7a	1740, 1730, 1660	1.53 (6H, s, 2CH ₃); 3.26 (2H, s, CH ₂); 3.89 (3H, s, OCH ₃); 3.94 (3H, s, OCH ₃); 7.23-7.35 (7H, m, Ar); 7.67 (1H, dt, $J = 8.0$, $J = 2.5$, Ar); 8.46 (1H, m, Ar)
7b	1732, 1726, 1701	1.51 (6H, s, 2CH ₃); 3.20 (2H, s, CH ₂); 3.80 (3H, s, OCH ₃); 3.89 (3H, s, OCH ₃); 3.93 (3H, s, OCH ₃); 6.82 (2H, m, Ar); 7.22-7.32 (7H, m, Ar)
8	1865, 1711, 1677; 2640-2580	0.92 (6H, s, 2CH ₃); 2.36 (5H, s, CH ₂ , CH ₃); 2.98 (2H, s, H-3a, H-6a); 7.38-7.62 (5H, m, Ar); 12.25 (1H, br. s, COOH); 13.12 (1H, br. s, COOH)
9	1760, 1715, 1661; 3180, 2660-2600	0.99 (3H, s, CH ₃); 1.06 (3H, s, CH ₃); 2.37 (3H, s, CH ₃); 2.47 (1H, d, $J = 9.0$, CH); 2.58 (1H, d, $J = 9.0$, CH); 3.43 (1H, d, $J = 18.0$, CH); 3.58 (1H, d, $J = 18.0$, CH); 4.12 (1H, dd, $J = 15.0$, $J = 5.0$, CH); 4.37 (1H, dd, $J = 15.0$, $J = 5.0$, CH); 7.01-7.21 (5H, m, Ar); 7.41 (1H, m, Ar); 8.02 (1H, d, $J = 8.0$, Ar); 8.04 (1H, dt, $J = 8.0$, $J = 2.0$, Ar); 8.51 (1H, m, Ar); 9.15 (1H, t, $J = 5.0$, NH); 13.94 (1H, br. s, COOH).

* The ^1H NMR spectra were recorded in CDCl_3 (compounds **1a-c**, **2a,b,d**, **4b**, **6c,d**, **7a,b**) and $\text{DMSO}-d_6$ (compounds **4a,c,d**, **5b,c**, **8**, **9**).




Fig. 1. Three-dimensional model of the molecule **4c** with the numbers of the atoms and the thermal vibration ellipsoids.

TABLE 3. The Crystallographic Data of Compound **4c**

Empirical formula	C ₁₉ H ₁₇ N ₅ O ₄
<i>M</i> _r	379.38
Crystal system	Monoclinic
Space group	<i>C</i> 2/ <i>c</i>
Unit cell parameters:	
<i>a</i> , Å	23.1182(5)
<i>b</i> , Å	9.8210(3)
<i>c</i> , Å	19.2573(4)
β, deg.	114.909(2)
<i>V</i> , Å ³	3965.4(2)
Molecular multiplicity, <i>Z</i>	8
Density of crystals, <i>d</i> , g/cm ³	1.271
Absorption coefficient, μ, mm ⁻¹	0.092
Number	
of independent reflections	5031
reflections with <i>I</i> > 2σ(<i>I</i>)	3411
refined parameters	265
Final <i>R</i> factor	0.0874
Employed programs	SIR97 [1], SHELXL97 [2]

TABLE 4. The Principal Bond Lengths (*l*) in the Molecule of Compound **4c**

Bond	<i>l</i> , Å	Bond	<i>l</i> , Å
N ₍₁₎ –N ₍₂₎	1.375(4)	C ₍₇₎ –C ₍₈₎	1.489(4)
N ₍₁₎ –C ₍₈₎	1.352(4)	C ₍₈₎ –C ₍₉₎	1.379(5)
N ₍₁₎ –C ₍₁₀₎	1.432(4)	N ₍₁₈₎ –N ₍₁₉₎	1.234(4)
N ₍₂₎ –C ₍₃₎	1.320(4)	N ₍₁₉₎ –C ₍₂₀₎	1.491(4)
C ₍₄₎ –C ₍₅₎	1.556(4)	C ₍₂₀₎ –C ₍₂₁₎	1.502(5)
C ₍₄₎ –C ₍₉₎	1.434(4)	C ₍₂₁₎ –O ₍₂₂₎	1.196(4)
C ₍₄₎ –O ₍₁₇₎	1.217(4)	C ₍₂₀₎ –C ₍₂₆₎	1.514(4)
C ₍₅₎ –C ₍₆₎	1.539(4)	C ₍₂₁₎ –O ₍₂₃₎	1.360(5)
C ₍₅₎ –N ₍₁₈₎	1.515(4)	O ₍₂₃₎ –C ₍₂₄₎	1.405(4)
C ₍₅₎ –C ₍₂₆₎	1.555(4)	C ₍₂₄₎ –O ₍₂₅₎	1.181(4)
C ₍₆₎ –C ₍₇₎	1.554(4)	C ₍₂₄₎ –C ₍₂₆₎	1.508(5)

TABLE 5. The Principal Valence (ω) and Torsion (τ) Angles in the Molecule of compound **4c**

Angle	ω , deg	Angle	τ , deg
N ₍₂₎ -N ₍₁₎ -C ₍₈₎	111.6(3)	C ₍₉₎ -C ₍₄₎ -C ₍₅₎ -C ₍₆₎	32.3(3)
N ₍₁₎ -N ₍₂₎ -C ₍₃₎	106.2(2)	C ₍₅₎ -C ₍₂₆₎ -C ₍₂₀₎ -C ₍₂₁₎	113.5(3)
C ₍₅₎ -N ₍₁₈₎ -N ₍₁₉₎	113.8(2)	N ₍₁₉₎ -C ₍₂₀₎ -C ₍₂₆₎ -C ₍₂₄₎	128.2(3)
N ₍₁₈₎ -N ₍₁₉₎ -C ₍₂₀₎	111.7(3)		
C ₍₂₁₎ -O ₍₂₃₎ -C ₍₂₄₎	110.8(3)		

EXPERIMENTAL

The IR spectra were obtained on a Specord IR-75 instrument for suspensions in vaseline oil (1800-1500 cm⁻¹) and hexachlorobutadiene (3600-2000 cm⁻¹). The frequencies of the stretching vibrations of the C-H bonds in the region of 3050-2800 cm⁻¹ are not given. The ¹H NMR spectra were recorded on a Varian Mercury BB spectrometer (200 MHz) with TMS as internal standard.

5-Diazo-6,6-dimethyl-1-phenyl (1a), 5-Diazo-3,6,6-trimethyl-1-phenyl- (1b), and 1-[(3,5-Bistrifluoromethyl)phenyl]-5-diazo-3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazoles (1d). The corresponding tosylhydrazone **2a,b,d** (2 mmol) was suspended in aqueous solution (40 ml) sodium hydroxide (0.4 g). The mixture was heated at 80-90°C with stirring for 1 h, and ethanol (15 ml) was added. The precipitate was filtered off, compounds **1a,b** were recrystallized from benzene-hexane and **1d** from ethyl acetate-hexane.

6,6-Dimethyl-4-oxo-1-phenyl-5-tosylhydrazono- (2a), 3,6,6-Trimethyl-4-oxo-1-phenyl-5-tosylhydrazono- (2b), and 1-[(3,5-Bistrifluoromethyl)phenyl]-3,6,6-trimethyl-4-oxo-5-tosylhydrazono-4,5,6,7-tetrahydroindazoles (2d). A solution of the corresponding 4,5-dioxo derivative (5 mmol) [10, 15] and tosylhydrazone (5 mmol) in ethanol (30 ml) was boiled for 2 h, cooled, and in the case of **2d** diluted with an equal quantity of water. The tosylhydrazone was filtered off and recrystallized from ethanol.

1',3'-Substituted 6',6'-Dimethyl-4,6,4'-trioxo-4,6,3a,6a,4',5',6',7'-octahydrospiro[3H-furo[3,4-c]-pyrazole-3,5'-indazoles] 4a-d. A solution of the corresponding diazoindazole **1a-d** (3 mmol) and maleic anhydride (3 mmol) in methylene chloride (30 ml) was left at 20°C for 15 days. The precipitate was filtered off, washed on the filter with methylene chloride, and recrystallized from ethyl acetate by briefly boiling.

1',3'-Substituted 6',6'-Dimethyl-2,4,4'-trioxo-4',5',6',7'-tetrahydrospiro[3-oxabicyclo[3.1.0]hexane-6,5'-indazoles] 5b,c. The pyrazolines **4b,c** in a wide test tube were immersed in an oil bath at 150°C for 2-3 min. Bubbles of nitrogen were released. The residue was recrystallized from ethanol.

The same compounds **5b,c** were obtained by boiling of the pyrazolines **4b,c** (5 mmol) in toluene (30 ml) for 2 h. The mixture was cooled, and the product was filtered off and recrystallized from ethanol.

2,3-Dicarboxy-5',3',6',6'-trimethyl-4'-oxo-1'-phenyl-4',5',6',7'-tetrahydrospiro[cyclopropane-1,5'-indazole] (8). The indazole spiro derivative **5b** (3 mmol) in 2% aqueous sodium hydroxide (3 ml) solution was heated to boiling, cooled, and acidified to pH 3-4 with hydrochloric acid. The precipitated dicarboxylic acid was filtered off and recrystallized from a solution of 1:1 ethanol-water.

3-Benzylaminocarbonyl-2-carboxy-5',3',6',6'-tetramethyl-4'-oxo-1'-(2-pyridyl)-4',5',6',7'-tetrahydrospiro[cyclopropane-1,5'-indazole] (9). To a solution of the anhydride **5c** (3 mmol) in dry benzene (30 ml) we added benzylamine (3.5 mmol). The mixture was boiled for 2-3 min and cooled. After 24 h the precipitated compound **9** was filtered off and recrystallized from acetic acid.

4,5-Dimethoxycarbonyl-3'-(4-methoxyphenyl)-3',6',6'-trimethyl-4'-oxo-1'-(2-pyridyl)- (6c) and 1'-[(3,5-Bistrifluoromethyl)phenyl]-4,5-dimethoxycarbonyl-3'-(4-methoxyphenyl)-3',6',6'-trimethyl-4'-oxo- (6d), 4,5-Dimethoxycarbonyl-3'-(4-methoxyphenyl)-6',6'-dimethyl-4'-oxo-3-phenyl-2'-(2-pyridyl)- (7a)

and **4,5-Dimethoxycarbonyl-3'-(4-methoxyphenyl)-6',6'-dimethyl-4'-oxo-2'-phenyl-4',5',6',7'-tetrahydro-spiro[3H-pyrazole-3,5'-indazole] (7b)**. A solution of the corresponding diazoindazole **1c,d** or **3a,b** (3 mmol) and dimethyl acetylenedicarboxylate (3 mmol) in methylene chloride (30 ml) was left at 20°C for four days. Hexane (60 ml) was added, and the precipitated pyrazoles **6c,d** and **7a,b** were recrystallized from ethanol.

X-ray Crystallographic Investigations (Tables 3-5). For X-ray crystallographic analysis the diffraction pattern of a single crystal of compound **4c**, measuring 0.05×0.26×0.33 mm, was recorded on an automatic Nonius KappaCCD diffractometer up to $2\theta_{\max} = 57^\circ$ ($\lambda_{\text{Mo}} = 0.71073 \text{ \AA}$).

REFERENCES

1. G. A. Nishiguchi, A. L. Rodriguez, and J. A. Katzenellenbogen, *Bioorg. Med. Chem. Lett.*, **12**, 947 (2002).
2. S. Löber, H. Hübner, and P. Gmeiner, *Bioorg. Med. Chem. Lett.*, **12**, 2377 (2002).
3. R. F. Kaltenbach, R. M. Klabe, B. C. Cordova, and S. P. Seitz, *Bioorg. Med. Chem. Lett.*, **9**, 2259 (1999).
4. E.-S. A. M. Badawey and I. M. El-Ashmawey, *Eur. J. Med. Chem.*, **33**, 349 (1998).
5. I. A. Strakova, L. G. Delyatitskaya, M. V. Petrova, and A. Ya. Strakov, *Khim. Geterotsikl. Soedin.*, 1209 (1998). [*Chem. Heterocycl. Comp.*, **34**, 1036 (1998)].
6. I. A. Strakova, A. Ya. Strakov, and M. V. Petrova, *Khim. Geterotsikl. Soedin.*, 962 (2000). [*Chem. Heterocycl. Comp.*, **36**, 847 (2000)].
7. I. A. Strakova, A. Strakovs, and M. Petrova, *Latv. J. Chem.*, 65 (2003).
8. I. Strakova, M. Petrova, and A. Strakovs, *Khim. Geterotsikl. Soedin.*, 1089 (2004). [*Chem. Heterocycl. Comp.*, **40**, 938 (2004)].
9. I. Strakova, A. Strakov, and M. Petrova, *Khim. Geterotsikl. Soedin.*, 740 (2005). [*Chem. Heterocycl. Comp.*, **41**, 637 (2005)].
10. I. Strakova, A. Strakovs, and M. Petrova, *Latv. J. Chem.*, 174 (2005).
11. I. A. Strakova, A. Ya. Strakov, and M. V. Petrova, *Khim. Geterotsikl. Soedin.*, 351 (1995). [*Chem. Heterocycl. Comp.*, **31**, 303 (1995)].
12. I. A. Strakova, A. Strakov, and M. Petrova, *Khim. Geterotsikl. Soedin.*, 1829 (2005). [*Chem. Heterocycl. Comp.*, **41**, 1507 (2005)].
13. R. Huisgen, *Angew. Chem.*, **75**, 604 (1963).
14. R. Huisgen, *Helv. Chim. Acta*, **50**, 2421 (1967).
15. E. Yu. Gudrinietse, I. Ya. Strakov, I. A. Strakova, D. R. Zitsane, and A. F. Ievinsh, *Dokl. Akad. Nauk*, **216**, 1293 (1974).
16. A. Altomare, M. Burla, M. Camalli, G. Cascarano, C. Giacovazzo, A. Guagliardi, A. Moliterni, and R. Spagna, *J. Appl. Crystallogr.*, **32**, 115 (1999).
17. G. M. Sheldrick (1997). *SHELXL-97. Program for the Refinement of Crystal Structures*, Univer. Göttingen, Göttingen, Germany (1997).